View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2011 FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria Cancer Lett. 2011 Apr 9. [Epub ahead of print]
2. 2011 Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma Oncol Rep. 2011 Jun;25(6):1533-9
3. 2011 Human CD59 inhibitor sensitizes rituximab resistant lymphoma cells to complement-mediated cytolysis Cancer Res. 2011 Mar 15; 71(6):2298-307. PMID: 21252115
4. 2011 Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells Cell Mol Immunol. 2011, Mar; 8(2): 157-63. PMID: 21258360
5. 2010 A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS J Immunol. 2010:184(1):359-68
6. 2010 Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice Circulation. 2010:121:1338-1346
7. 2010 The Critical Roles of Platelet Activation and Reduced NO Bioavailability in Fatal Pulmonary Arterial Hypertension in a Murine Hemolysis Model Blood, 2010 Sep 2;116(9):1613-22.
8. 2010 ELAV like HuR-dependent mRNA stability regulates post-transcriptional expression of cyclin dependent kinase inhibitor p27KIP1 Journal of Biological Chemistry. 2010, 285(20):15408-19.
9. 2010 The good and evil of complement activation in HIV-1 infection. Cell Mol Immunol. 2010 Sep; 7(5):334-40
10. 2009 Anaphylatoxin C5a Contributes to the Pathogenesis of Cisplatin-induced Nephrotoxicity Am J Physiol Renal Physiol. 2009;296(3):F496-504
11. 2009 Curcumin improves spatial memory impairment induced by human immunodeficiency virus type 1 glycoprotein 120 V3 loop peptide in rats Life Sciences. 2009, 85(1-2), 1-10
12. 2009 Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex Circulation Research. 2009; 104(4):550-558
13. 2009 The balancing role of nitric oxide in complement-mediated platelet activation of mCd59a and mCd59b double-knockout mice American Journal of Hematology. 2009;84(4):221-227
14. 2008 The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy The Oncologist. 2008;13(9):854-966.
15. 2008 Generation and phenotyping of a mCd59a and mCd59b double-knockout mice American Journal of Hematology. 2008;84:65-70
16. 2008 Conditional, rapid and targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nature Medicine. 2008;14:98-103
17. 2006 The complement system in liver diseases Cell Mol Immunol. 2006;3(6):333-340
18. 2006 Analysis of the Promoters and 5’-UTR of Mouse Cd59 Genes, and of their Functional Activity in Erythrocytes Genes and Immunity. 2006;7(4):287-297.
19. 2005 Further characterization of the reproductive abnormalities in mCd59b knockout mice: A potential new function of mCd59 in male reproduction Journal of Immunolgy. 2005;175(10):6294-9302.
20. 2004 Toward the generation of mouse models for studying the pathogenesis of complement mediated human diseases Immunology 2004. 2004: pp. 63-67
21. 2004 Glycation-inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human disease Diabetes. 2004;53:2653-2661
22. 2004 Complement and complement regulatory proteins as potential molecular targets for vascular diseases Current Pharmaceutical Design. 2004;10:203-211
23. 2003 Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility Immunity. 2003;18:217-227.
24. 2002 Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse American Journal of Human Genetics. 2002;70:324-335
25. 2001 Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b Mammalian Genome. 2001;12:582-589
26. 2000 Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59 J Immunol. 2000;165:2528-2534
27. 1997 Isolation of 28 new STSs at Xq27.3 Acta Academiae Medicinae Sinicae. 1997;19(1):1-5
28. 1996 Construction of a Chinese cosmid library Acta Academiae Medicinae Sinicae. 1996;18(5):333-337.
29. 1996 Study on the polymorphism of intron 13 (CA)n repeat within FVIII gene in Chinese and its application for the diagnosis of hemophilia A. Journal of Chinese Blood. 1996;17(3):121-124
30. 1996 Alternative splicing expression of FMR-1 gene in human fetal neuron. Am J Med Genet. 1996;64(2):252-255
31. 1995 Artificial chromosome vector system as important tools in genome and gene function researches. Foreign Medical Science (Genetics). 1995;18(5):250-252
32. 1995 Detection of hypermethylation in affected males with fragile X syndrome by PCR assay. Acta Academiae Medicinae Sinicae. 1995;17(1):47-51
33. 1994 Unstable DNA sequence and methylation in fragile X syndrome National Medical Journal of China. 1994;74(10):611-614.
34. 1994 Molecular mechanism of fragile X syndrome. Foreign Medical Science (Genetics). 1995;18(2):78-80.
35. 1993 An explanation of the genetic phenomena of 4 fragile X families by using Laird's X-inactivation imprinting hypotheses Chinese Journal of Medical Genetics. 1993;10(2):119-120.
36. 1993 A study of fragile X syndrome in cytogenetics and clinic characteristics Chinese Journal of Medical Genetics. 1993;10(1):14–17.
37. 1992 Looking for an internal control system for fragile X induction system Chinese Journal of Medical Genetics. 1992;9(6):354-355
38. Cytolytic peptides are an emerging class of promising cancer therapeutics shown to overcome drug resistance. Pubmed Cytolytic peptides are an emerging class of promising cancer therapeutics shown to overcome drug resistance. They eliminate cancer cells via disruption of the phospholipid bilayer of cell membranes, a mechanism that differentiates it from traditional treatments. However, applications of lytic peptides via systematic administration are hampered by nonspecific toxicity. Here, we describe activatable, masked lytic peptides that are conjugated with anionic peptides via a cleavable linker sensitive to matrix metalloproteinases (Ac-w-βA-e8-XPLG*LAG-klUklUkklUklUk-NH2; lower case letters in the sequences represent D-amino-acids, U=Aib, α-aminoisobutyric acid, *cleavage site). The peptides were activated upon being introduced into the triple negative breast cancer cell line MDA-MB-231, which overexpresses secreted matrix metalloproteinases, to selectively cleave the peptide linker. Our results indicate that the activatable design could be applied to improve the targeting ability of lytic peptides.

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.